Clinical TrialApr 23, 2026, 07:03 AM
Psyence BioMed Doses First Patient in Phase IIb Psilocybin Trial
AI Summary
Psyence Biomedical Ltd. announced the dosing of the first patient in its Phase IIb clinical trial for NPX-5 (25mg nature-derived psilocybin). This trial targets Adjustment Disorder in cancer patients within a palliative care setting, aiming to evaluate the safety and efficacy of the treatment. The initiation of dosing marks a significant step in generating human data and advancing the company's vertically integrated biopharmaceutical platform.
Key Highlights
- First patient dosed in Phase IIb trial for NPX-5 (25mg psilocybin).
- Trial targets Adjustment Disorder in cancer patients in palliative care.
- Study conducted across five clinical sites in Australia.
- Aims to evaluate safety, efficacy, and treatment durability.
Price Impact
More from PBM